Compare HFFG & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HFFG | MNOV |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | United States | United States |
| Employees | 960 | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.7M | 67.9M |
| IPO Year | 2016 | 2004 |
| Metric | HFFG | MNOV |
|---|---|---|
| Price | $1.50 | $1.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 113.7K | 36.0K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.65 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $1,228,282,000.00 | $2,360,807.00 |
| Revenue This Year | $5.59 | N/A |
| Revenue Next Year | $2.24 | $180.00 |
| P/E Ratio | $75.00 | ★ N/A |
| Revenue Growth | 2.21 | ★ 194.15 |
| 52 Week Low | $1.38 | $1.17 |
| 52 Week High | $3.86 | $1.96 |
| Indicator | HFFG | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 37.96 | 47.47 |
| Support Level | $1.40 | $1.30 |
| Resistance Level | $2.30 | $1.46 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 11.54 | 33.33 |
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, frozen and dry food, and non-food products to Asian restaurants and other foodservice customers throughout the United States. The company's business consists of one operating segment: HF Group, which operates solely in the United States. The company's product list consists of Meat, Poultry & Seafood, Sauces & Oils, Takeout Items (Boxes, Chopsticks & Utensils), Raw Ingredients (Flour, Cornstarch, Spices), Cleaning Supplies, and Rice & Grains.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.